FOX04-DRI

FOX04-DRI

FOX04-DRI

FOXO4-DRI is a senolyt compound also known as the IT-Inhibitor peptide which shows promising anti-aging properties.

 

 

SKU: 198628 Category:
Share your love

Substantial research into cellular senescence mechanisms has led to the development of FOXO4-DRI, a senolytic compound also known as the IT-Inhibitor peptide. This bioactive peptide shows promising anti-aging properties.

In senescent cells, for instance, FOXO4 binds to p53, forming a complex known as FOXO4-p53 aggregates. This complex acts as an inhibitor of apoptosis initiation. Consequently, this interaction extends the lifespan of cellular senescence and leads to their accumulation over time.

Notably, FOXO4-DRI does not directly target FOXO1, FOXO3, or p53 proteins. Instead, it specifically interacts with FOXO4’s binding site within the FOXO4-p53 complex. This interaction promotes the complex’s dissociation, releases p53, and thereby re-activates p53-induced apoptosis, all while sparing normal cells from side-effects.

Several reports demonstrate the potent efficacy of FOXO4-DRI in selectively killing senescent cells. Furthermore, studies indicate that FOXO4-DRI reverses age-associated physiological decline: it increases physical endurance and motor performance, restores renal function and hair growth, and thereby slows down age-related tissue decay. For example, aged mouse models clearly show these benefits. Additionally, FOXO4-DRI reduces chronic inflammation and tissue damage in the post-chemotherapy microenvironment, thus improving the quality of life and promoting long-term health in cancer patients.

Sequence

H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-OH

CAS Number

2460055-10-9

Molecular Formula

C228H388N86O64

Molecular Weight

5358.05

Research Of Foxo4-dri Benefits

1.Selective Induction of Senescent Cell Apoptosis

The primary mechanism of FOXO4-DRI involves the specific stimulation of programmed cell death in senescent cells. Here, p53 operates as a trans-activating factor for pro-apoptotic genes, inducing apoptosis. However, under normal physiological conditions, the FOXO4-p53 complex represses this apoptotic function.

By competing for p53 binding, FOXO4-DRI disrupts the FOXO4-p53 interaction. This disruption initiates the intrinsic apoptosis pathway specifically in senescent cells.

In aged mice, treatment with FOXO4-DRI led to hair regrowth comparable to middle-aged mice and significantly enhanced motor performance.

2.Quality of Life for Cancer Patients

Researchers are exploring FOXO4-DRI as a potential adjuvant drug to improve the quality of life for cancer patients after chemotherapy. While numerous anticancer agents affect tumor cells, they also cause non-specific injury to normal cells, increasing the burden of therapy-induced senescence(TIS).

Extensive studies validate that FOXO4-DRI can efficiently eliminate both spontaneous and treatment-induced senescent cells, ameliorating chemotherapy-induced frailty syndrome. For instance, a study in Cell  demonstrated improved recovery and survival in chemotherapy-treated mice. These findings highlight the strong adjuvant therapeutic potential of FOXO4-DRI in oncology.

3.Ameliorating Liver Disease Pathology

In NASH(Nonalcoholic steatohepatitis) patients, senescent cells accumulate in the liver and secrete pro-inflammatory and pro-fibrotic molecules via the senescence-associated secretory phenotype (SASP), driving disease progression. Studies using a mouse NASH model found that FOXO4-DRI eliminated these hepatic senescent cells, suppressing SASP production at its source.

4.Treatment of Mice with Bleomycin-Induced Pulmonary Fibrosis

FOXO4-DRI triggers selective p53 nuclear exclusion and dissociation of the FOXO4-p53 complex. In bleomycin-induced mouse models, treatment with FOXO4-DRI decreased levels of Collagen, type I, alpha 1 (Col1a1) and α-SMA in lung tissues. This reduction suggests decreased production of extracellular matrix and inhibition of myofibroblast activation.

Although the study did not fully elucidate the precise pathway of FOXO4-DRI’s interaction with p53, it clearly demonstrated effective inhibition of fibrosis, highlighting a potential therapeutic strategy for idiopathic pulmonary fibrosis (IPF).

5.Alleviating Age-Related Hypogonadism (Testosterone Deficiency)

Male late-onset hypogonadism is an aging-related dysfunction impairing aged Leydig cells. Clearing these senescent cells can rejuvenate tissue function. Studies show that FOXO4-DRI acts specifically on human testicular Leydig cells. Administering it to aged mice improved the testicular microenvironment, preventing age-related testosterone deficiency. A 2021 study reported a significant increase in serum testosterone levels in treated aged mice.

The proposed mechanism involves specific suppression of p53 nuclear localization and dissociation of the FOXO4-p53 complex, resulting in senescent-cell apoptosis. These results suggest a potential therapeutic avenue for treating age-associated testosterone reduction.  

COA

HPLC

MS

(1) Kong, Y.-X.; Li, Z.-S.; Liu, Y.-B.; Pan, B.; Fu, X.; Xiao, R.; Yan, L. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology 2025, 8 (1). DOI: 10.1038/s42003-025-07738-0.

(2) Baar, M. P.; Brandt, R. M. C.; Putavet, D. A.; Klein, J. D. D.; Derks, K. W. J.; Bourgeois, B. R. M.; Stryeck, S.; Rijksen, Y.; van Willigenburg, H.; Feijtel, D. A.; et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell 2017, 169 (1), 132-147.e116. DOI: 10.1016/j.cell.2017.02.031.

(3) Tajar, A.; Forti, G.; O’Neill, T. W.; Lee, D. M.; Silman, A. J.; Finn, J. D.; Bartfai, G. r.; Boonen, S.; Casanueva, F. F.; Giwercman, A.; et al. Characteristics of Secondary, Primary, and Compensated Hypogonadism in Aging Men: Evidence from the European Male Ageing Study. The Journal of Clinical Endocrinology & Metabolism 2010, 95 (4), 1810-1818. DOI: 10.1210/jc.2009-1796.

(4) Liu, Y.; Hou, Q.; Wang, R.; Liu, Y.; Cheng, Z. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg’s Archives of Pharmacology 2023, 396 (10), 2393-2403. DOI: 10.1007/s00210-023-02452-2.

(5) Zhang, C.; Xie, Y.; Chen, H.; Lv, L.; Yao, J.; Zhang, M.; Xia, K.; Feng, X.; Li, Y.; Liang, X.; et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging 2020, 12 (2), 1272-1284. DOI: 10.18632/aging.102682.

specification

10 mg, 5 mg

Sequence:

H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-OH

CAS:

2460055-10-9

M.W:

5358.15 g/mol